Vaxdyn has worked on transforming AcinetoVax, a monovalent vaccine candidate, into a technological platform able to deliver multi-valent vaccines for raising immunity against several superbacteria with a single vaccine.

The first multi-valent candidate KapaVax has been designed to raise immunity against Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, the top-3 superbacteria of urgent risk of the list of the World Health Organization.

These 3 pathogens are responsible for more than 40% of pneumonia cases that do not respond to available antibiotics. Creating immunity against these superbacteria is an urgent need for populations in the community with chronic lung disease, as those affected by chronic obstructive pulmonary disease (COPD), cystic fibrosis or primary ciliary dyskinesia. It is also an urgent need to prevent secondary infections in patients admitted to hospital with high probability of receiving mechanical ventilation, like Covid-19 affected patients, or patients admitted for certain surgical procedures or transplants.

By using the same proprietary technology Vaxdyn is widening its pipeline to deliver vaccine candidates targeting other populations in urgent need, like women with recurrent urinary-tract infections produced by antibiotic-resistant uropathogenic Escherichia coli or Klebsiella pneumoniae.

Powered by CARB-X

Vaxdyn’s candidate KapaVax is supported by the international organization headquartered in Boston CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator). Vaxdyn is the first Spanish biotech to be funded by CARB-X, a global non-profit partnership investing $500 million in the development of innovative vaccines, antibiotics and rapid diagnostics to fight drug-resistant bacteria around the world.

Contact supplier

Stay in the loop!